Clinical trial Recruiting at 1 site Interventional Ages 12 to 18

High-definition tDCS targeting the primary somatosensory cortex for adolescent bipolar depression

Official title: High-Definition Transcranial Direct Current Stimulation (HD-tDCS) Targeting the Primary Somatosensory Cortex for Bipolar Depression in Adolescents: A Randomized Double-Blind Controlled Trial

Run by Jiangsu Province Nanjing Brain Hospital · NCT07246044 · Data updated 2026-11-12

This trial will try high-definition transcranial direct current stimulation (HD-tDCS) to reduce depressive symptoms in adolescents aged 12–18 with bipolar depression, compared with a sham procedure.

Quick facts

Study typeInterventional
Ages12 Years to 18 Years
SexAll
Enrollment100 (estimated)
SponsorJiangsu Province Nanjing Brain Hospital
Academic / other
Locations1 site (Nanjing, Jiangsu)
StatusRecruiting
StartedOctober 15, 2025
Main results expectedDecember 31, 2027
Study endsDecember 31, 2027
Registry record updatedOctober 27, 2026
Trial IDNCT07246044 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are 12–18 years old, meet DSM criteria for bipolar disorder with a current moderate-to-severe depressive episode (HAMD ≥17 and YMRS <12), are on a stable psychotropic medication regimen, and can provide informed consent with parental permission as required.

Probably not a fit

Patients with prior brain stimulation (rTMS/tDCS/ECT), uncontrolled or unstable medication or manic symptoms, inability to undergo MRI, or who cannot attend the required in-person twice-daily sessions are unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, double-blind, sham-controlled trial enrolling adolescents with bipolar depression to receive either active HD-tDCS or sham stimulation alongside routine clinical care. Active or sham stimulation is delivered for 10 consecutive days with two 20-minute sessions per day. Multimodal assessments are performed at baseline, mid-treatment, and post-treatment and include clinical scales, neurocognitive testing, structural and functional MRI, blood biomarkers, EEG, photoplethysmography, voice and facial metrics, sleep, and behavioral data. The study also seeks objective biomarkers and neurobiological mechanisms that predict or accompany clinical response to S1-targeted HD-tDCS.

Why it matters

Potential benefit: If successful, this noninvasive approach could provide a tolerable, clinic-delivered option to reduce depressive symptoms in adolescents with bipolar disorder and help identify biomarkers to personalize care.

How similar studies have gone: Some adult tDCS studies have shown modest antidepressant effects, but HD-tDCS targeting the primary somatosensory cortex in adolescents with bipolar depression is a novel and relatively untested approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Between 12 and 18 years of age;
* Participants fulfill the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnostic criteria for bipolar disorder (BD). Participants are assessed by the Structured Clinical Interview for DSM-IV for Axis I Disorders (SCID-I, patients' age ≥18 years old), or the Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version (K- SADS-PL, patients' age\< 18 years old);
* A current moderate or severe depressive episode defined by HAMD≥17 and Young Mania Rating Scale (YMRS) \<12;
* Participants receive a stable psychotropic medication regimen prior to randomization to the trial and are willing to remain on the stable regimen during the HD-tDCS treatment phase;
* Participants and 1 or 2 parents (patients' age\< 18 years old) provide informed consent after the detailed description of the study.

Exclusion Criteria:

* Prior rTMS or tDCS or electroconvulsive therapy (ECT) treatment or standard psychological therapy within 6 months prior to screening;
* Comorbidity of other DSM-IV axis I disorders or personality disorders;
* Judged clinically to be at serious suicidal risk;
* Diabetes mellitus, hypertension, vascular and infectious diseases and other major medical comorbidities;
* Unstable medical conditions, e.g., severe asthma;
* Neurological disorders, e.g., history of head injury with loss of consciousness for ≥ five minutes, cerebrovascular diseases, brain tumors and neurodegenerative diseases;
* Mental retardation or autism spectrum disorder;
* Contraindications to MRI (e.g., severe claustrophobia, pacemakers, metal implants);
* Contraindications to tDCS (e.g., metal in head, history of seizure, EEG test suggesting high risk of seizure, known brain lesion);
* Current drug/alcohol abuse or dependence;
* Pregnant or lactating female.

Where it's running

  • Affiliated Nanjing Brain Hospital, Nanjing Medical University
    Nanjing, Jiangsu, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.